Has Naomi Watts confirmed using HRT?

Yes. Watts has confirmed HRT use in multiple public interviews, including with People magazine, The New York Times, and Today. She has spoken about beginning perimenopause at 36 and choosing hormone therapy as part of her treatment plan.

What happens to menopause symptoms when you stop HRT?

Hot flashes and night sweats return in about half of women who discontinue, often within weeks. Bone density gains are typically lost within 2 to 3 years. Genitourinary symptoms like vaginal dryness will resume or progress, since they are estrogen-dependent and do not resolve on their own after menopause.

Is there a maximum recommended duration for HRT?

No fixed maximum exists in current guidelines. Both NAMS and the British Menopause Society recommend individualized duration decisions based on ongoing symptom burden, personal risk factors, and annual reassessment with a provider.

Is tapering off HRT better than stopping suddenly?

Clinical evidence does not show a clear advantage for tapering over abrupt cessation in terms of symptom recurrence rates. Many clinicians still prefer gradual dose reduction as a practical approach, but this is based on clinical experience rather than strong trial data.

Does early menopause change the risk-benefit calculation for HRT?

Yes. Women who enter menopause before 45, and especially before 40, are generally advised to use HRT at least until the average age of natural menopause (around 51) to protect cardiovascular, bone, and cognitive health. The timing hypothesis suggests that earlier initiation relative to menopause onset carries a more favorable risk profile.

Naomi Watts, Maintenance, and What Happens If You Stop

By HealthRX Medical Team

Published May 25, 2026Updated May 25, 2026Last reviewed May 25, 2026

The Public Record: Naomi Watts and HRT

Naomi Watts has been unusually candid about her menopause experience. In a 2023 interview with People magazine, she described being told she was in perimenopause at 36, a diagnosis that shaped both her personal health decisions and her business trajectory. She confirmed pursuing hormone therapy as part of her treatment plan and has spoken about it in multiple outlets, including interviews with Today and The New York Times.

Watts launched Stripes Beauty in 2022, a brand explicitly designed around menopause symptom management. The company sells topical products alongside educational content about hormonal health. In press interviews for the brand, Watts has repeatedly stated that she uses HRT and considers it a critical part of managing her symptoms.

This is not speculation. Watts has confirmed HRT use on the record, in her own words, across multiple interviews.

Why Discontinuation Matters Clinically

For millions of women on HRT, the question of "how long do I stay on this?" is among the most common and most anxiety-producing. The 2022 position statement from The North American Menopause Society (NAMS) acknowledges that decisions about duration should be individualized, but many patients receive unclear or inconsistent guidance from providers.

The clinical conversation around HRT duration was shaped heavily by the Women's Health Initiative (WHI), a large randomized trial published in 2002 in JAMA. The WHI's initial findings suggested increased breast cancer and cardiovascular risk with combined estrogen-progestin therapy, leading to a dramatic drop in prescriptions. Subsequent reanalysis, including the 2017 JAMA follow-up, showed that younger women (those within 10 years of menopause onset) had a more favorable risk-benefit profile than the original headlines suggested.

That reanalysis matters here. Watts entered perimenopause early. Women who begin HRT closer to menopause onset generally face lower cardiovascular risk and may derive more benefit from sustained therapy, according to the "timing hypothesis" supported by observational and trial data.

What Happens When You Stop HRT

Discontinuation of HRT triggers a set of predictable physiological responses. The HealthRX Medical Team breaks these into three categories.

Vasomotor symptom return. Hot flashes and night sweats recur in an estimated 50% of women who stop HRT, regardless of how long they were on therapy. A randomized trial published in Menopause found that symptoms returned within weeks of cessation in the majority of participants, and about one-third reported symptom severity equal to or worse than their pre-treatment baseline.

Bone density decline. Estrogen is a primary regulator of bone remodeling. The WHI extension study demonstrated that bone mineral density gains achieved during HRT were lost within 2 to 3 years of stopping. For women who began therapy partly due to osteopenia or fracture risk, discontinuation without a transition plan (such as bisphosphonate therapy) may create a measurable clinical gap. The Endocrine Society's clinical practice guidelines recommend assessing bone density before and after HRT cessation.

Urogenital and vaginal atrophy progression. Genitourinary syndrome of menopause (GSM), which includes vaginal dryness, irritation, and urinary symptoms, is estrogen-dependent and does not resolve spontaneously after menopause. When systemic HRT stops, GSM symptoms typically resume or worsen. Low-dose vaginal estrogen, which carries a different risk profile than systemic therapy, is often continued independently, as outlined in ACOG's practice bulletin.

Tapering vs. Abrupt Cessation

There is no strong randomized evidence favoring gradual dose reduction over abrupt cessation. A 2004 Cochrane-adjacent analysis found no statistically significant difference in symptom recurrence between the two approaches. In practice, many clinicians still recommend tapering (reducing dose by half for 3 to 6 months before stopping) as a pragmatic strategy to ease the transition. The British Menopause Society also supports individualized tapering as a reasonable clinical approach, though it stops short of calling it evidence-based.

The HealthRX Medical Team notes that patient preference and psychological readiness play a large role. Women who feel in control of the process, whether tapering or stopping on a defined schedule, tend to report better subjective outcomes. This is a domain where shared decision-making between patient and provider carries real weight.

Long-Term Maintenance: What the Data Supports

For women who continue HRT beyond the conventional 5-year window, what does the evidence say?

The 2019 Lancet meta-analysis of worldwide epidemiological data confirmed that breast cancer risk increases with duration of combined estrogen-progestin use, with excess risk appearing after approximately 5 years and persisting for several years after cessation. Estrogen-only therapy (used in women without a uterus) carries a lower breast cancer signal. The absolute risk increase is modest but real: approximately 1 additional case per 50 women using combined HRT for 5 to 14 years.

Cardiovascular data is more reassuring for women who start early. The Danish Osteoporosis Prevention Study (DOPS), published in the BMJ, followed women for 16 years and found reduced cardiovascular mortality in the early-start HRT group with no increase in cancer, stroke, or venous thromboembolism.

Cognitive outcomes remain contested. The WHIMS study suggested increased dementia risk with late initiation of HRT (age 65+), but the ELITE trial and observational Finnish registry data suggest potential neuroprotective effects when therapy begins within 5 years of menopause.

The HealthRX Medical Team Take

Watts represents a specific clinical profile: a woman who entered perimenopause early, began HRT relatively close to symptom onset, and has remained on therapy as part of an integrated approach to menopausal health. For this profile, the evidence generally supports continued use with periodic reassessment rather than arbitrary discontinuation at a fixed time point.

The HealthRX Medical Team emphasizes three principles for women in similar situations:

Annual reassessment, not automatic renewal. Every year on HRT should include a conversation about symptom burden, risk factors (particularly breast density and family history), and whether the therapy still aligns with the patient's goals.
Bone density monitoring at discontinuation. If a woman decides to stop, a DEXA scan before cessation and 1 to 2 years after provides actionable data about whether alternative bone-protective therapy is needed.
GSM treatment should be uncoupled from systemic HRT decisions. Vaginal estrogen can often continue indefinitely at low dose, even after systemic therapy ends, per FDA labeling and NAMS guidance.

Watts' public advocacy has contributed to reducing stigma around menopause treatment. Her openness about early perimenopause, in particular, helps normalize a clinical reality that affects roughly 1% of women under 40 (premature ovarian insufficiency) and a larger percentage in their early-to-mid 40s.

At a glance

Status: Naomi Watts has publicly confirmed using HRT for perimenopause symptoms that began at age 36
Business connection: Founded Stripes Beauty (2022), a menopause-focused consumer brand
Discontinuation risk: ~50% of women experience vasomotor symptom return; bone density losses within 2-3 years
Long-term use: Combined HRT beyond 5 years carries a small but measurable breast cancer risk increase; estrogen-only therapy has a lower signal
Early-start advantage: Women beginning HRT within 10 years of menopause onset have a more favorable cardiovascular risk profile
Clinical guidance: Annual reassessment, bone monitoring at cessation, and continued low-dose vaginal estrogen for GSM are standard recommendations

Frequently asked questions

›

References

Writing Group for the Women's Health Initiative. "Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women." JAMA (2002). pubmed.ncbi.nlm.nih.gov/12117397
Manson JE et al. "Menopausal Hormone Therapy and Long-term All-Cause and Cause-Specific Mortality." JAMA (2017). jamanetwork.com
Schierbeck LL et al. "Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women (DOPS)." BMJ (2012). pubmed.ncbi.nlm.nih.gov/23042362
Collaborative Group on Hormonal Factors in Breast Cancer. "Type and timing of menopausal hormone therapy and breast cancer risk." The Lancet (2019). thelancet.com
Henderson VW et al. "Cognitive effects of estradiol after menopause (ELITE)." JAMA Neurology (2016). pubmed.ncbi.nlm.nih.gov/27071068
The North American Menopause Society. "2022 Hormone Therapy Position Statement." menopause.org
Ockene JK et al. "Symptom experience after discontinuing use of estrogen plus progestin." Menopause (2005). pubmed.ncbi.nlm.nih.gov/21444883
Eastell R et al. "Postmenopausal osteoporosis." Endocrine Society Clinical Practice Guideline. pubmed.ncbi.nlm.nih.gov/30476057